乳腺癌患者高危型人乳头状瘤病毒感染、p53蛋白表达及淋巴结转移分析

目的分析乳腺癌患者高危型人乳头状瘤病毒（HPV）感染、p53蛋白表达和淋巴结转移率。 方法选取2016年5月至2018年5月于西北妇女儿童医院治疗的乳腺癌患者共90例作为观察组,选取同期于本院治疗乳腺增生患者90例作为对照组。对癌组织行HPV基因分型和p53蛋白检测,增生组织行HPV基因分型。观察入组患者高危型HPV感染率,分析乳腺癌患者肿瘤大小、TNM分期、淋巴结转移率与p53蛋白表达等。 结果观察组患者中共60例发生高危型HPV感染,对照组中共36例发生高危型HPV感染,观察组患者中HPV16、18基因型感染率分别为21.11%（19/90）和22.22%（20/90）,均高于对照组[2.22%（2/90）和2.22%（2/90）],差异均有统计学意义（χ² = 7.108、P = 0.001,χ² = 8.063、P = 0.001）。观察组HPV阳性患者淋巴结转移率为93.33%（56/60）,显著高于HPV阴性患者（21/30、70.00%）,差异有统计学意义（χ² = 4.072、P = 0.002）。观察组患者中p53蛋白阳性者39例（39/90、43.33%）,其中肿瘤大小≤ 2 cm者27例（27/39、69.23%）、TNM分期Ⅰ期、Ⅱ期、Ⅲ期和Ⅳ期分别占15.38%（6/39）、30.77%（12/39）、35.90%（14/39）和17.95%（7/39）,淋巴结转移率为82.05%（32/39）;p53蛋白阴性患者51例（51/90,56.67%）,肿瘤大小≤ 2 cm者35例（35/51、68.63%）、TNM分期Ⅰ期、Ⅱ期、Ⅲ期和Ⅳ期分别占7.84%（4/51）、19.61%（10/51）、49.02%（25/51）和23.53%（12/51）,淋巴结转移率为86.27%（44/51）,p53蛋白阴性组与p53蛋白阳性组患者肿瘤大小、TNM分期及淋巴结转移率差异均无统计学意义（χ² = 0.682、P = 0.462,χ² = 0.491、P = 0.507,χ² = 0.572、P = 0.461）。 结论检测乳腺癌患者高危型人乳头状瘤病毒感染、p53蛋白表达及淋巴结转移率有助于对乳腺癌的诊疗;p53蛋白阳性率下降可能促进HPV感染相关肿瘤的发生和发展。     

2-Week wait referrals in suspected skin cancer: Does an instructional module for general practitioners improve diagnostic accuracy?

The two-week wait (2WW) scheme in the United Kingdom for suspected skin cancer has been criticised for having low pick up rates, with a high proportion of clinically benign lesions being referred as suspicious.We studied the referral patterns of skin cancer to our hospital under the 2WW initiative, and aimed to quantify the effect of a targeted continuing medical education (CME) module on improving diagnostic accuracy.All referrals to our hospital (dermatology and plastic surgery) under the 2WW rule were audited between July and September 2006. A targeted CME module was sent to GPs describing and illustrating common lesions. After 11 months, all 2WW referrals were prospectively studied between August and October 2007. The main outcome measure was the percentage of correctly referred squamous cell carcinomas (SCCs) and melanomas.237 referrals were made between July and August 2006, and 223 referrals between August and October 2007. The proportion of appropriately referred skin cancers (SCCs and melanomas) was 23.2% before CME, and 20.6% after CME. There were no differences in pick up rates before and after the CME amongst suspected SCCs (21.1% vs. 29.7%) or melanomas (24.6% vs. 15.1% respectively). Referrals to Plastic Surgery were more likely to be confirmed histologically as melanomas or SCCs (23.6% and 33.7% respectively) than those made to Dermatology (17.5% and 15.3% respectively).The proportion of correctly suspected skin malignancies under the 2WW initiative remains low despite education. A targeted CME module sent to GPs fails to improve pick up rates. There is a need for continuing dermatology training amongst referring physicians.     

前列腺癌MTS_1-P_(16)与突变P_(53)的表达研究

应用单克隆抗体(MTS_1-P_(16(C-20))、PAb-DO-1-P_(53)免疫组化技术对38例高、中、低三种不同分化的前列腺癌MTS_1-P_(16)与突变P_(53)的表达率进行了比较研究。结果显示:在高、中、低三种不同分化的前列腺癌组织切片中MTS_1-P_(16)的阳性表达率为46.2％、21.4％和10％:突变P_(53)的阳性表达率为38.5％、71.4％和72.7％。MTS_1-P_(16)与突变P_(53)总的阳性表达率为23.6％和60.5％。结果提示:MTS_1-P_(16)的表达率随细胞分化恶化而丢失;突变P_(53)随细胞分化恶化表达率升高,MTS_1-P_(16)与P_(53)的丢失、突变与过度表达与肿瘤的发生及恶性生物学行为有关,同时测定MTS_1-P_(16)与突变P_(53)可作为评价前列腺癌预后新的生物学指标。     

P53、P16、TGF-α、EGFR、VEGF在膀胱移行细胞癌组织中的表达及意义

目的探讨P53、P16、TGF-α、EGFR、VEGF在膀胱移行细胞癌组织中的表达及意义。方法采用免疫组化法,对膀胱移行细胞癌P53、P16、TGF-α、EGFR、VEGF表达、缺失及生物学意义进行了研究。结果60例膀胱移行细胞癌患者中有68.3%（41/60）TGF-α阳性表达,EGFR阳性表达率35%（21/60）,VEGF阳性表达率50%（30/60）,P53阳性表达率38.3%（23/60）,P16阳性表达率30%（18/60）。结论P16阳性表达率与患者的性别无明显相关性、随肿瘤分级和分期增高而降低,而P53、P16、TGF-α、EGFR、VEGF的表达率随肿瘤分级、分期的升高而明显增高,并且多个基因的共同表达也随着肿瘤分级、分期的升高而明显增高。     

Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas: A Breslow Thickness Cut Point of 0.8 mm Separates Higher-Risk and Lower-Risk Tumors

Background

Counterintuitively, more deaths from melanoma occur among patients with thin (T1) primary melanomas (≤ 1 mm) than among those with thick primary melanoma because the great majority present with T1 tumors. Therefore, it is important to stratify their risk as accurately as possible to guide their management and follow-up. This study sought to explore the relationship between tumor thickness and prognosis for patients with thin primary melanomas.

Methods

A retrospective, single-institution study investigated 6263 patients with cutaneous melanoma (including 2117 T1 cases) who had a minimum follow-up period of 10 years.

Results

For the entire patient cohort, the 10-year melanoma-specific survival (MSS) rate ranged between 92% for the patients with primary melanomas up to 0.3 mm thick and 32% for those with melanomas thicker than 8 mm. When divided into 25-quantile-thickness groups there was a significant difference in 10-year MSS between the two consecutive groups 0.8 and 0.9 mm; the differences in survival were not significantly different for any other consecutive cut points within the less than or equal to 1 mm thickness range, indicating a biologically-relevant difference in outcome above and below 0.8 mm. For the patients treated initially at the authors’ institution, the 10- and 20-year MSS rates for those with tumors up to 0.8 mm thick were respectively 93.4 and 85.7%, and for tumors 0.9 to 1.0 mm, the rates were respectively 81.1 and 71.4%. Only 29.3% of the T1 patients who died of melanoma were deceased within 5 years.

Conclusions

A naturally occurring thickness cut point of 0.8 mm predicts higher or lower risk for patients with thin primary cutaneous melanomas. Long-term follow-up assessment of patients with T1 melanoma is important because late mortality due to melanoma is more common than early mortality.

     

Prognostic factors in supratentorial WHO grade II astrocytoma in adults

The records of 33 adult patients with supratentorial World Health Organization grade II astrocytoma (A-II) treated between January 1980 and April 1997 at our hospitals were retrospectively reviewed. All tumours were surgically resected or biopsied and their MIB-1 labelling indices (LIs) were less than 1.5%. The median time to tumour progression after the initial surgery was 60 months, and the 5- and 10-year tumour progression-free rates were 53 and 39%, respectively. The median survival time was 107 months, and the 5- and 10-year survival rates were 66 and 43%, respectively. The major cause of death was tumour recurrence with malignant transformation, comprising 93% of all deaths due to unrestrained tumour growth. In a univariate analysis for survival rate by log-rank test, age (< 60 years), Karnofsky Performance Scale score (90-100%), tumour location (except for the basal ganglia), and extent of surgery (more than biopsy) were revealed to be significant positive prognostic factors. A Cox proportional hazard multivariate regression analysis confirmed that the age was the only independent, significant positive prognostic factor in this series. The survival time after the initial surgery in patients without radiotherapy tended to be prolonged compared with those of the patients with radiotherapy. Of the 26 patients who received radiotherapy, however, the survival time after the initial surgery in the nine patients with intraoperative radiotherapy was significantly prolonged compared with the 17 patients who received sole external beam radiotherapy. Gender, symptoms, histology, p53 LI, enhancement on CT/MRI, cyst, calcification and chemotherapy were not shown to be significant prognostic factors. The optimal management strategy for A-II is expected to be established by clarification of the natural history with cytological and molecular biological analyses of the biological features of this disease.     

Retroperitoneal sarcomas: grade and survival

BACKGROUND: The survival of patients with retroperitoneal sarcomas depends on the feasibility of complete resection and the grade of the tumor. HYPOTHESIS: A high rate of complete resection, wide rather than local excision when feasible, and a policy of prompt reoperation for local recurrence all improve survival. METHODS: A review of 130 consecutive patients with retroperitoneal soft tissue sarcomas (1977-2001). RESULTS: The complete resectability rate was 95%, being 99% (78/79) for the primary tumors and 90% (46/51) for tumors referred with local recurrence. Local recurrence after complete resection occurred in 41% (32/79) of those with primary tumors and in 61% (31/51) of those referred with local recurrence (P =.06). The local recurrence rate was 63% after local excision and 39% after wide resection (P =.02). Of 83 patients with relapse, 37 (45%) were rendered surgically disease free. The estimated 5-year (10-year in parentheses) survival from the first surgery at our center was 65% (56%) for patients with primary tumors and 53% (34%) for patients referred with local recurrence (P =.23). For the primary tumors, the 5- and 10-year survival rates were 70% and 60%, respectively, after wide resection and 47% and 39%, respectively, after local excision (P =.04). For the primary tumors, the 5-year survival was 92%, 54%, and 48% for grades I, II, and III, respectively (P =.02). For those referred with local recurrence, the figures were 76%, 45%, and 19% for grades I, II, and III, respectively (P<.001). CONCLUSIONS: A high resectability rate (95%) is possible in retroperitoneal sarcomas. The survival estimates are similar to those following resection of extremity soft tissue sarcomas given an effective reoperation policy for local recurrences. Wide resection lowers the local recurrence and improves survival significantly. Survival varies significantly according to the grade of the tumor.     

Long-Term Results of a Prospective Surgical Trial Comparing 2 cm vs. 4 cm Excision Margins for 740 Patients With 1–4 mm Melanomas

Background:The Intergroup Melanoma Surgical Trial began in 1983 to examine the optimal surgical margins of excision for primary melanomas of intermediate thickness (i.e., 1–4 mm). There is now a median 10-year follow-up.Methods:There were two cohorts entered into a prospective multi-institutional trial: (1) 468 patients with melanomas on the trunk or proximal extremity who randomly received a 2 cm or 4 cm radial excision margin and (2) 272 patients with melanomas on the head, neck, or distal extremities who received a 2 cm radial excision margin.Results:A local recurrence (LR) was associated with a high mortality rate, with a 5-year survival rate of only 9% (as a first relapse) or 11% (anytime) compared with an 86% survival for those patients who did not have a LR (P < .0001). The 10-year survival for all patients with a LR was 5%. The 10-year survival rates were not significantly different when comparing 2 cm vs. 4 cm margins of excision (70% vs. 77%) or comparing the management of the regional lymph nodes (observation vs. elective node dissection). The incidences of LR were the same for patients having a 2 cm vs. 4 cm excision margin regardless of whether the comparisons were made as first relapse (0.4% vs. 0.9%) or at anytime (2.1% vs. 2.6%). When analyzed by anatomic site, the LR rates were 1.1% for melanomas arising on the proximal extremity, 3.1% for the trunk, 5.3% for the distal extremities, and 9.4% for the head and neck. The most profound influence on LR rates was the presence or absence of ulceration; it was 6.6% vs. 1.1% in the randomized group involving the trunk and proximal extremity and was 16.2% vs. 2.1% in the non-randomized group involving the distal extremity and head and neck (P < .001). A multivariate (Cox) regression analysis showed that ulceration was an adverse and independent factor (P = .0001) as was head and neck melanoma site (P = .01), while the remaining factors were not significant (all with P > .12).Conclusion:For this group of melanoma patients, a local recurrence is associated with a high mortality rate, a 2-cm margin of excision is safe and ulceration of the primary melanoma is the most significant prognostic factor heralding an increased risk for a local recurrence.Presented at the 53rd Annual Cancer Symposium of the Society of Surgical Oncology at New Orleans, LA, on March 18, 2000     

Effect of hormonal therapy on 18F-fluciclovine PET/CT in the detection of prostate cancer recurrence,localization of metastatic disease,and correlation with prostate-specific antigen

Introduction¹⁸F-Fluciclovine, is a positron emission tomography (PET) radiotracer approved for the localization of sites of prostate cancer recurrence in men with a rising prostate-specific antigen (PSA) after definitive treatment. To explore the impact of androgen deprivation therapy (ADT) on the performance of ¹⁸F-fluciclovine, we conducted a retrospective analysis to compare the ¹⁸F-fluciclovine PET/CT positivity rate in patients receiving ADT at the time of the scan with the rate achieved in patients not receiving ADT.MethodsA retrospective review of data from patients who underwent ¹⁸F-fluciclovine PET/CT for biochemical recurrence of prostate cancer between December 2016 to March 2020 was performed. The cohort was divided into an ADT group (patient reportedly on ADT) and a non-ADT group (not currently receiving ADT). Patients with unknown ADT status or undetectable/unknown PSA were excluded. For each group, the number of positive ¹⁸F-fluciclovine PET/CT scans (positivity rate) was evaluated for the whole body, prostate/bed, and extraprostatic regions and rates were correlated with PSA. The Fisher's Exact test was applied to establish the significance between the ADT and non-ADT positivity groups. Mantel-Haenszel trend test was performed to assess linearity between the positivity rate and PSA level.ResultsIn 320 patients, the status of ADT was known. At the time of the ¹⁸F-fluciclovine scan, 68/320 (21%) patients were on ADT, while 252/320 (79%) were not. The median Gleason score was 8 (range of 6–10) in the ADT group vs. 7 (range of 6–10) in the non-ADT group (P < 0.001). Overall, positivity rates demonstrated no statistical significance between the ADT and non-ADT groups; Positivity rates (ADT vs. non-ADT) were 82% (56/68) vs. 82% (206/252) for the whole body, 57% (39/68) vs. 60% (152/252) for prostate/bed, and 60% (41/68) vs. 53% (133/252) for extraprostatic regions (P > 0.05). A positive linear correlation was noted between PSA and each group's positivity rate (P < 0.01). However, no significant difference was observed between ADT and non-ADT groups at different PSA levels (P > 0.05).ConclusionsDetection of prostate cancer recurrence with ¹⁸F-fluciclovine PET/CT is not significantly influenced by ADT, suggesting that localization of disease in patients with detectable PSA who are receiving ADT is feasible with ¹⁸F-fluciclovine.     

How far is the preoperative Kattan nomogram applicable for the prediction of recurrence after prostatectomy in patients presenting with PSA levels of more than 20 ng/ml? A validation study

OBJECTIVE: We present an external validation study investigating the applicability of the preoperative Kattan nomogram for predicting recurrence after prostatectomy in a population of patients with serum prostate-specific antigen (PSA) levels exceeding 20 ng/ml. MATERIALS: In the evaluation of clinical parameters pooled from a total of 191 patients presenting with PSA levels ranging between 20.1 and 100 ng/ml, the PSA-free survival rate 60 months after surgery was calculated according to Kattan nomograms. Subsequently, the results were statistically compared with the corresponding actual survival rates obtained from Kaplan-Meier analysis. For this purpose, the patients were assigned to one of four different risk groups according to predictions derived from the Kattan nomograms, enabling a direct comparison of expected (as predicted by Kattan nomogram) versus actual survival of each patient investigated in our study. RESULTS: Predicted PSA-free survival rates were determined to be as follows: 83% (low risk group); 66% (intermediate risk group); 39% (intermediate-high risk group), and 10% (high risk group) in comparison with the actual survival rates determined to be 63, 62, 40 and 21%, respectively. For PSA levels ranging between 20.1 and 30 ng/ml, 30.1 and 50 ng/ml, and 50.1 and 100 ng/dl, PSA-free survival rates were found to be 57, 37, and 27% (p=0.0017), respectively, during a 5-year post-prostatectomy follow-up. CONCLUSIONS: The Kattan nomogram shows good statistical concordance with actual survival rates in the mean risk quadrants, but considerable differences were demonstrated concerning individuals with either a high or with a low risk of cancer progression.     

p53、bcl-2、c-erbB-2在胃癌及癌前病变中表达的意义

目的：研究p53、bcl-2、c-erbB-2基因在胃癌及癌前病变中的表达，探讨其与胃癌发生的关系。方法：采用免疫组化SABC法，检测p53、bcl-2、c-erbB-2基因蛋白在98例胃癌、39例肠上皮化生、40例不典型增生和20例正常胃粘膜中的表达。结果：①p53在胃癌中的阳性表达率为55．1％，早期胃癌和进展期胃癌分别为50．0％，55．4％；在肠上皮化生中的表达率为12．8％，与早期胃癌比较有统计学差异（P〈0．05），随不典型增生程度的加重p53的表达率逐渐升高，依次为5％，20％，60％，其中轻中度与重度不典型增生差异有统计学意义（P〈0．05），而在正常胃粘膜中未见p53表达②bcl-2在正常胃粘瞑中有弱阳性表达（10．0％），在不典型增生中为50．0％，在胃癌中为44．9％，不典型增生与胃癌中的表达均显著高于正常胃粘膜（P〈0．05）。③c-erbB-2在胃癌中的阳性表达率为55．1％，其中在早期胃癌中的表达率较低（16．7％），在重度不典型增生和进展期胃癌中的表达率较高，分别为60．0％和57．6％，二者与早期胃癌比较差异有统计学意义（P〈0．05）。④c-erbB-2表达与肿瘤浸润深度、淋巴结转移有关（P〈0．05），与胃癌分化程度无关（P〉0．05）；bcl-2表达与胃癌的分化程度有关（P〈0．05），低分化者bcl-2表达率高，与淋巴结转移，浸润深度无关（P〉0．05）；p53表达与上述临床病理因素均无关（P〉0．05）。结论：p53，bcl-2，c-erbB-2参与了胃粘膜的癌变过程。     

蒙古族睾丸肿瘤35例临床分析

目的:提高对蒙古族睾丸肿瘤的诊断和治疗水平。方法:多中心回顾性分析1990年2月~2004年12月35例蒙古族睾丸肿瘤患者的临床资料。结果:主要症状为无痛性睾丸肿大或结节。平均延误诊断(40.03±53.45)周,16例(45.7%)延迟诊断6个月~5年。睾丸肿瘤病理类型:精原细胞瘤21例(60%),占生殖细胞瘤的67.7%(21/31),非精原细胞瘤10例(28.6%),恶性淋巴瘤2例(5.7%),神经纤维瘤和平滑肌瘤各1例(5.7%)。生殖细胞瘤I期22例,II期2例,III期5例。治疗手段以睾丸肿瘤根治性切除和放疗及化疗为主。随访29例睾丸恶性肿瘤患者2个月~10年,其中精原细胞瘤20例,3、5年生存率分别为95.0%、95.0%;非精原细胞瘤7例,3、5年生存率分别为57.1%、42.8%;2例恶性淋巴瘤患者,1例健在,1例化疗中。结论:本组蒙古族睾丸肿瘤患者精原细胞瘤比例高于一般人群,平均延误诊断时间较长。非精原细胞瘤患者3、5年生存率均低于精原细胞瘤患者。睾丸肿瘤知识的宣教和诊疗技术的提高,有助于改善睾丸肿瘤患者的疗效和预后。     

The Dornier Compact Delta lithotripter: the first 500 renal calculi

BACKGROUND AND PURPOSE: Extracorporeal Shockwave Lithotripsy (SWL) is now the best noninvasive treatment for renal calculi, rendering many patients stone free. This prospective study was performed to evaluate the short-term results of patients undergoing SWL with the Dornier Compact Delta lithotripter for all renal calculi. PATIENTS AND METHODS: Between April 1999 and May 2000, there were 500 renal calculi treated in 166 female and 334 male patients with a mean age of 53 +/- 15 years. All patients who completed treatment were entered in the study and assessed at 1 and 3 months with a plain film of the kidneys, ureters, and bladder. Stone-free rate and final outcome have been evaluated. Final outcome is defined as stone free or residual fragments 4 mm or less. Analysis has been made according to stone size, location, number of treatments per stone, and number of shocks per stone. The analgesia requirements during each treatment and complications have also been analyzed. RESULTS: The overall stone-free rate for stones <10 mm was 62% at 1 month and 76% at 3 months. For stones 10 to 20 mm, these rates were 53% and 66%, while the rates for stones >20 mm were 41% and 47%, respectively. The final outcome for stones <10 mm was 90% at 1 month and 93% at 3 months, for stones 10 to 20 mm 73% and 84%, and for stones >20 mm 57% and 67%, respectively. The effectiveness quotient for calculi <10 mm was 60%. For calculi 10 to 20 mm, it was 51%, and for those >20 mm, it was 31%. Oral analgesia was given routinely; however, additional intravenous analgesia was necessary in 22% of treatments. No serious complications have been seen. CONCLUSIONS: These results show that with proper patient selection, good results at 1 and 3 months can be achieved with minimal anesthesia during treatment and low retreatment rates. We do not recommend SWL as primary therapy for stones >20 mm.     

Immunohistochemical evaluation of p53, proliferating cell nuclear antigen (PCNA) and bcl-2 expression during bacillus calmette-guerin (BCG) intravesical instillation therapy for superficial bladder cancers

Bacillus Calmette-Guerin (BCG) immunotherapy for superficial bladder cancer is now widespread, but non-effective cases are not uncommon and it has yet to be clarified why this is the case. In an attempt to cast light on this problem, we evaluated differences between effective and non-effective cases immunohistochemically using p53, proliferating cell nuclear antigen (PCNA), and bcl-2 antibodies. Between March 1988 and March 1996 a total of 79 superficial bladder cancer patients were treated with BCG intravesical instillation therapy after transurethral resection of bladder tumor (TUR-Bt). Of these, 19 demonstrated recurrence after the initial treatment. From the 60 remaining patients without recurrence, we randomly chose 19 additional cases and evaluated both series for p53, PCNA and bcl-2 immunohistochemical staining using formalin-fixed, paraffin-embedded tissues. For the recurrent cases, material taken prior and subsequent to BCG therapy was available for 17 of the 19 patients. Positive staining for p53 was noted for 42.1% (8/19) of both recurrent and non-recurrent cases, without any difference between the two. The rates for PCNA and bcl-2 were 52.6% (10/19) and 47.4% (9/19) in recurrent, and 36.8% (7/19) and 78.9% (15/19) in non-recurrent cases, respectively. Thus, there was a significant difference for lower incidences of bcl-2 in recurrent cases (P=0.044). Values for p53 and bcl-2 were respectively 47.1% (8/17) and 41.2% (7/17) pre-treatment, and 52.9% (9/17) and 35.3% (6/17) post-treatment in the recurrence group. In contrast to the similarity in these results, PCNA positive cases were 52.9% (9/17) pre-treatment and 17.6% (3/17) post-treatment. These data suggest that there are differences between BCG-sensitive and BCG-resistant bladder cancers in terms of bcl-2 expression. Received: 25 August 1997 / Accepted: 5 February 1998     

Establishment and characterization of human urothelial cancer xenografts in severe combined immunodeficient mice

AIM: To establish and characterize a murine xenograft model of human urothelial cancer in severe combined immunodeficient (SCID) mice for therapeutic simulation. METHODS: Pieces of 30 freshly resected urothelial tumors (24 obtained from bladder and 6 from ureter or pelvis) were implanted subcutaneously into SCID mice, and xenograft tumors were passed in tumorigenic cases. At each passage, histopathology, TP53 mutational status assessed by yeast p53 functional assay, and the Ki-67 labeling index (LI) were examined to evaluate the preservation of original features. A growth delay assay after single-dose irradiation was performed in four representative xenografts. RESULTS: Tumor growth was observed in 18 mice (60%, 18/30). Histologically, 15 of the 18 were epithelial carcinomas similar to the original tumors, whereas the other 3 were Epstein-Barr virus-associated lymphoproliferative disease, resulting in a 50% (15/30) take rate. No correlation was found between the tumor take rate and the clinicopathologic features, TP53 mutational status, or Ki-67 LI of the patients' tumors. Of these 15 xenografts, 11 xenografts were passed from 3 to 10 generations. TP53 mutational status remained stable during the passages, and the Ki-67 LI of eight xenografts was within a range of 50% of the LI of the original tumors, although the other three xenografts increased by over 50%. Specific growth delay after irradiation, independent of the original tumor growth speed and Ki-67 LI, was observed in four xenografts. CONCLUSIONS: SCID mice are useful recipients for investigations of human urothelial cancer with a wide biological range. This easy-to-handle xenograft system can help to develop a better in vivo preclinical evaluation system for therapeutic agents as well as the investigation of tumor pathophysiology.     

P33ING1在肛管癌中的表达及与P53和细胞凋亡的关系

目的探讨P33ING1在肛管癌中的表达及与P53和细胞凋亡的关系。方法应用免疫组织化学SP法检测42例肛管癌标本中P33ING1和P53的表达,同时检测其细胞凋亡,并与肛管腺瘤和乳头状瘤及肛周炎性肿块对照组比较。结果在肛管癌、肛管腺瘤及乳头状瘤、肛周炎性肿块组织中P33ING1阳性表达率分别为40．5%、97．2%及97．5%；P53分别为50．O%、22．2%及27．5%；平均细胞凋亡指数则分别为(10．27±1．23)‰、(42．67±1．04)‰及(42．75±0．98)‰。肛管癌中P33ING1、P53阳性率及平均细胞凋亡指数与另外两组比较,差异有统计学意义(P＜0．05)。在P53表达阳性的21例病例中有18例P33ING1表达阴性。结论P33ING1在肛管癌组织中低表达,对肛管癌的发生、发展可能起重要作用。P33ING1和P53互相协同,抑制细胞生长、促进调亡。     

Long-term follow-up of exercise tolerance after coronary bypass grafting]

Six hundred forty-eight serial graded exercise tests were performed on 400 patients up to 10 years after coronary bypass graftings (CABG). The maximal attained exercise tolerance, over 10 METS, were observed in 60% of patients and the negative response to exercise test in 43% of patients. The positive response in various parameters were observed at the following rates: graft occlusion-30% vs graft patent-46% (p less than 0.01); incomplete revascularization-39% vs complete revascularization-22% (p less than 0.01); and less than or equal to 8 METS 4-45% vs greater than or equal to 10 METS-28% (p less than 0.01), respectively. However, no significant difference was observed among number of vessels diseased, number of graftings, and presence of old myocardial infarction. The maximal attained stage of exercise, over 10 METS, in various parameters were at the following rates: less than or equal to 59 years old-70% vs greater than or equal to 60 years old-44% (p less than 0.01); male-63% vs female-32% (p less than 0.01); and graft patent-63% vs graft occlusion-50% (p less than 0.05), respectively. The serial analysis of exercise test demonstrated that improved exercise tolerance appears to persist for at least 5 years after CABG. However, the patients in complete revascularization had a tendency to increase the rate of positive response. In conclusion, the completeness of revascularization as well as graft patency was the main factor limiting exercise tolerance, and correlates with the extent and the duration of improvement after CABG.     

The impact of patient delay and physician delay on the outcome of laparoscopic cholecystectomy for acute cholecystitis

BACKGROUND: Laparoscopic cholecystectomy is now used in the management of acute cholecystitis. Under these circumstances unfavorable conditions may result in conversion and complications. Information about these conditions may help in planning the laparoscopic approach or in proceeding directly to open cholecystectomy. This study was initiated to evaluate perioperative factors associated with conversion and complications of laparoscopic cholecystectomy in acute cholecystitis. Special attention was paid to the duration of complaints until surgery, to the delay on the part of the patient, and to the delay on the part of the physician. METHODS: Between January 1994 and December 1997, we attempted to perform laparoscopic cholecystectomy on 348 patients with acute cholecystitis. All perioperative data were collected on standardized forms. RESULTS: There were 182 cases (52%) of acute uncomplicated cholecystitis, 90 (26%) of gangrenous cholecystitis, 33 of hydrops (9.5%), and 43 of empyema of the gallbladder (12.5%). Seventy six patients (22%) needed conversion to open cholecystectomy and complications occurred in 57 cases. Advanced cholecystitis was associated with significant patient delay (P = 0.01), and it had a significantly higher conversion rate (39%) compared with early cholecystitis (14.5%); (P <0.00001). Conversion rates were also associated with male gender (P = 0.0017), a history of biliary disease (P = 0.0085), and a patient delay of >48 hours (P = 0.028). The total and infectious complication rates were associated with an age older than 60 years (P = 0.023 and 0.007, respectively) and male gender (P = 0.026 and 0.014, respectively). CONCLUSIONS: In acute cholecystitis, patient delay is associated with a high conversion rate. Early timing of laparoscopic cholecystectomy tends to reduce the conversion rate, as well as the total and the infectious complication rates. Male gender, a history of biliary disease, and advanced cholecystitis are associated with conversion. Male and older patients are associated with a high total and infectious complication rates.     

Effectiveness of noncontrast computed tomography in evaluation of residual stones after percutaneous nephrolithotomy

PURPOSE: We prospectively compared the sensitivity of antegrade pyelography (AGP), plain film radiography (KUB film), and noncontrast thin-slice abdominal CT for detecting residual stones after percutaneous nephrolithotomy (PCNL). PATIENTS AND METHODS: We prospectively evaluated 50 patients (53 renal units) who underwent PCNL for radiopaque renal pelvic stones with noncontrast abdominal CT 1 month postoperatively. We compared the number and size of residual fragments, as determined by immediate postoperative AGP and 1-month KUB film and CT scan. RESULTS: Stone-free rates according to AGP, KUB film, and noncontrast CT were 73.6% (39/53), 62.3% (33/53), and 20.8% (11/53), respectively. However, if clinically insignificant residual fragments are included in the success rates, these rates increased to 84.9% (45/53), 83.0% (44/53), and 41.5% (22/53), respectively. Of the 22 patients in whom residual stones were detected by CT but not by KUB film, 10 (45.5%) had stones >4 mm in diameter on CT, with a mean size of 7.4 mm. The sensitivity for the detection of residual fragments was 47.6% for KUB films as judged by noncontrast CT. After CT, seven patients received extracorporeal shockwave lithotripsy for residual stones. CONCLUSIONS: Noncontrast thin-slice abdominal CT was the most accurate imaging method to determine the stone-free rate after PCNL. Noncontrast abdominal CT gives accurate information for selecting patients who may benefit from additional treatment and for planning follow-up.     

Long-Term Results of a Multi-Institutional Randomized Trial Comparing Prognostic Factors and Surgical Results for Intermediate Thickness Melanomas (1.0 to 4.0 mm)

BACKGROUND: Ten- to 15-year survival results were analyzed from a prospective multi-institutional randomized surgical trial that involved 740 stages I and II melanoma patients with intermediate thickness melanomas (1.0 to 4.0 mm) and compared elective (immediate) lymph node dissection (ELND) with clinical observation of the lymph nodes as well as prognostic factors that independently predict outcomes. METHODS: Eligible patients were stratified according to tumor thickness, anatomical site, and ulceration, and then prerandomized to either ELND or nodal observation. By using Cox stepwise multivariate regression analysis, the independent predictors of outcome were tumor thickness (P < .001), the presence of tumor ulceration (P < .001), trunk site (P = .003), and patient age more than 60 years (P = .01). RESULTS: Overall 10-year survival was not significantly different for patients who received ELND or nodal observation (77% vs. 73%; P = .12). Among the prospectively stratified subgroups of patients, 10-year survival rates favored those patients with ELND, with a 30% reduction in mortality rate for the 543 patients with nonulcerated melanomas (84% vs. 77%; P = .03), a 30% reduction in mortality rate for the 446 patients with tumor thickness of 1.0 to 2.0 mm (86% vs. 80%; P = .03), and a 27% reduction in mortality rate for 385 patients with limb melanomas (84% vs. 78%; P = .05). Of these subgroups, the presence or absence of ulceration should be the key factor for making treatment recommendations with regard to ELND for patients with intermediate thickness melanomas. CONCLUSIONS: These long-term survival rates from patients treated at 77 institutions demonstrate that ulceration and tumor thickness are dominant predictive factors that should be used in the staging of stages I and II melanomas, and confer a survival advantage for these subgroups of prospectively defined melanoma patients.